Exposure to long-acting injectable and oral second-generation antipsychotics during pregnancy was associated with similar obstetric outcomes in a large retrospective study.
Hydroxyzine is used frequently for the management of anxiety and sleep problems during pregnancy. However, there is limited information regarding its reproductive safety.
After accounting for potential confounding factors, including depression in the mother, there is little evidence of any association between antidepressant use during pregnancy and miscarriage.
In women with ADHD, about 60% of women with ADHD elect to discontinue ADHD medications around the time of conception.
After accounting for maternal depression, there is little evidence of any association between antidepressant use during pregnancy and miscarriage.
A systematic review examines neurodevelopmental outcomes in children prenatally exposed to antiepileptic drugs.
There is evidence that depression itself can increase risk for preeclampsia. In women with more severe depression, treatment with an SSRI antidepressant may decrease risk.
The current study observed no significant differences in overall developmental outcomes or behavior in exposed versus unexposed children.
More study is needed regarding the safety of sedative-hypnotic medications during pregnancy.
Dr. Marlene Freeman recently shared her insights on Psychiatric Medications and Considerations for Individuals Across Pregnancy, the Postpartum, and Reproductive Years with the National Alliance on Mental Illness on March 7, 2024.
